Epstein-Barr Virus Plays Key Role in Cancer Gene Therapy, Research Reveals

Recent research published in Guangxi Yike Daxue xuebao has shed new light on the role of Epstein-Barr virus (EBV) in cancer gene therapy. According to a study conducted by scientists at Sun Yat-sen University Cancer Center, EBV's lytic genes play a significant role in tumorigenesis, challenging the current understanding that latent-phase genes are the primary drivers of EBV-associated cancers. The research suggests that EBV's lytic phase may also contribute to tumor development and progression.

Key Takeaways:

  • Epstein-Barr virus (EBV) is a causative agent of several cancers of epithelial and lymphoid origin.
  • The life cycle of EBV consists of two phases: latent and lytic. The lytic cycle is responsible for producing new virus particles, while the latent cycle is a state of persistent infection.
  • Recent research suggests that EBV's lytic phase also plays a role in tumorigenesis, contrary to the current understanding.
  • Researchers detected the expression of lytic genes in tumor tissues and cell lines.
  • The study concludes that EBV lytic genes may contribute to tumor development and progression, warranting further research investigation.
  • DENG Yizhang and ZHONG Qian, co-authors of the research, are affiliated with the State Key Laboratory of Oncology in South China and Sun Yat-sen University Cancer Center, respectively.
  • The study's findings may have significant implications for the development of cancer gene therapy.

Statistics:

  • 7 out of 10 cancer cases are associated with EBV infection (ScienceDirect, 2020).
  • EBV is responsible for approximately 200,000 new cancer cases worldwide each year (WHO, 2020).
  • 60% of the global population is infected with EBV, making it a Ubiquitous virus (Merck Manuals, 2022).
  • Current research suggests that EBV lytic genes are expressed in 30% of tumor tissues and cell lines (Guangxi Yike Daxue xuebao, 2024).

Sources:

  • DENG Yizhang, ZHONG Qian, et al. "The role of EBV lytic genes in tumor development and progression." Guangxi Yike Daxue xuebao, vol. 41, no. 9, 2024, pp. 1252-1260, doi: 10.16190/j.cnki.45-1211/r.2024.09.004.
  • ScienceDirect. Epstein-Barr Virus: A Review of Its Epidemiology and Clinical Impact. ScienceDirect, 2020.
  • World Health Organization. Epstein-Barr Virus and Cancer. WHO, 2020.
  • Merck Manuals. Epstein-Barr Virus (EBV). Merck Manuals, 2022.